You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR T790M

Showing 1 - 25 of 3,258
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Lung Cancer Stage IV
  • EGFR T790M
  • Seoul, MA, Korea, Republic of
    Samsung Medical Center
Jan 26, 2023

EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)

Recruiting
  • EGFR T790M
  • +3 more
  • Beijing, Beijing, China
    Junling Li
Jul 21, 2022

Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • EGFR T790M
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 18, 2022

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    Lung Cancer Trial in Boston, Nashville

    Active, not recruiting
    • Lung Cancer
      • Boston, Massachusetts
      • +1 more
      Dec 28, 2022

      NSCLC Trial (Chemotherapy, Alflutinib plus chemo)

      Not yet recruiting
      • NSCLC
      • (no location specified)
      Jan 25, 2022

      NSCLC With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors Trial in Seoul

      Active, not recruiting
      • Non-Small Cell Lung Cancer With EGFR T790M Mutation
      • +2 more
      • Seoul, Korea, Republic of
        Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
      Aug 8, 2021

      Osimertinib for HK Chinese With Metastatic T790M Mutated

      Completed
      • Non-small Cell Lung Cancer
      • Hong Kong, China
      • +3 more
      Sep 7, 2021

      Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

      Recruiting
      • Bronchial Neoplasms
      • Cologne, Germany
      • +6 more
      Nov 2, 2022

      Lazertinib Dose Modification on Effectiveness and Safety

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Busan, Korea, Republic of
      • +10 more
      Jan 29, 2023

      Osimertinib in Advanced Non-Small Cell Lung Cancer EGFR-T790M

      Completed
      • Non Small Cell Lung Cancer
      • Oviedo, Asturias, Spain
      • +30 more
      Jun 1, 2022

      Metastatic NSCLC Trial in China (AC0010)

      Active, not recruiting
      • Metastatic Non-small Cell Lung Cancer
      • Beijing, Beijing, China
      • +16 more
      Sep 2, 2021

      Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation Trial in Shanghai (Almonertinib, Pemetrexed, Carboplatin)

      Unknown status
      • Lung Cancer, Non-small Cell
      • +2 more
      • Shanghai, Shanghai, China
        Cancer hospital Fudan University
      Oct 15, 2020

      Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

      Active, not recruiting
      • Carcinoma, Non-Small-Cell Lung
        • Hollywood, Florida
        • +1 more
        Sep 29, 2021

        NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

        Terminated
        • Carcinoma, Non-Small-Cell Lung
        • Kashiwa, Chiba, Japan
        • +3 more
        Jan 31, 2023

        Non Small Cell Lung Cancer Trial in Worldwide (AZD9291)

        Active, not recruiting
        Has Results
        • Non Small Cell Lung Cancer
        • La Jolla, California
        • +43 more
        Nov 25, 2022

        Lung Cancer Trial (Lazertinib 240 mg)

        Approved for marketing
        • Lung Cancer
        • Lazertinib 240 mg
        • (no location specified)
        Feb 15, 2022

        NSCLC Stage IV, EGFR T790M Trial in Shanghai (3rd generation EGFR-TKI, Consolidative SBRT)

        Recruiting
        • NSCLC Stage IV
        • EGFR T790M
        • 3rd generation EGFR-TKI
        • Consolidative SBRT
        • Shanghai, China
          Fudan University Shanghai Cancer Center
        Feb 19, 2021

        NSCLC Trial in Spain (Osimertinib)

        Completed
        • Non-Small Cell Lung Cancer
        • Barcelona, Spain
        • +6 more
        Nov 25, 2020

        NSCLC Trial in Beijing, Nanjing, Suzhou (BPI-7711 Capsule)

        Completed
        • Non-small Cell Lung Cancer
        • BPI-7711 Capsule
        • Beijing, Beijing, China
        • +3 more
        May 13, 2022

        Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

        Active, not recruiting
        • Small Cell Carcinoma
        • +3 more
        • Palo Alto, California
        • +9 more
        May 12, 2022

        AZD9291 Treatment in T790M Positive Non-small Cell Lung Cancer

        Completed
        • Non Small Cell Lung Cancer
          • Kaohsiung, Taiwan
          • +6 more
          Dec 17, 2020

          Combination of Osimertinib and Aspirin to Treat 1st Generation

          Unknown status
          • Non-Small Cell Lung Cancer Stage IIIB
          • +2 more
          • (no location specified)
          Jul 22, 2020

          Non Small Cell Lung Cancer (NSCLC) Trial in India (Osimertinib)

          Completed
          Has Results
          • Non Small Cell Lung Cancer (NSCLC)
          • Hyderabad, India
          • +6 more
          May 10, 2021

          Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

          Recruiting
          • Lung Neoplasms
          • +23 more
          • La Jolla, California
          • +35 more
          Oct 6, 2022